How Collaboration Between MAH, QP, and CDMO Improves Compliance Outcomes
Pharmaceutical compliance is foundational to safe and effective medicines. Achieving regulatory compliance in the EU/UK supply chain requires seamless coordination between the Marketing Authorisation Holder (MAH), the Qualified Person (QP), and the Contract Development and Manufacturing Organisation (CDMO). When these functions operate in isolation, gaps in quality oversight, documentation, and regulatory interpretation can result in inspection findings, delayed batch release, or market withdrawals. Because pharmaceutical quality and compliance are non-negotiable, modern manufacturing programmes integrate cross-functional collaboration to meet global Good Manufacturing Practices (GMP) and regulatory expectations without compromise.
What is an MAH, QP, and CDMO?
Pharmaceutical professionals and non-specialist readers should understand these core roles:
Marketing Authorisation Holder (MAH):
The MAH is the legal entity holding the authorisation to place a medicine on the market. It bears accountability for product quality, safety, and compliance throughout its lifecycle from development to post-approval changes and pharmacovigilance.
Qualified Person (QP):
Under EU and UK regulations, a QP is a scientifically qualified professional responsible for certifying that every batch of medicinal product complies with applicable GMP and is suitable for release. QP batch certification cannot be delegated and is required prior to market entry.
Contract Development and Manufacturing Organisation (CDMO):
A CDMO performs outsourced development and manufacturing services on behalf of a sponsor or MAH. CDMOs support analytical method development, scale-up, process validation, and batch production but must align with the MAH’s quality systems and regulatory strategy.
Clear, documented responsibilities among these stakeholders are critical to avoid regulatory missteps especially in multinational contexts.
Why Compliance Failures Happen in Outsourced Manufacturing
Outsourcing manufacturing or testing does not diminish quality obligations. Common compliance failure modes include:
- Miscommunication : Lack of shared expectations on quality standards between MAH, QP, and CDMO.
- Unclear Responsibilities : Ambiguous quality agreement terms can lead to gaps in quality control.
- Documentation Gaps : Incomplete batch records, inadequate deviation documentation, or missing CAPA follow-up can trigger inspection actions.
- Regulatory Interpretation Differences : Divergent interpretations of EU/UK GMP or national requirements can stymie compliance outcomes.
Effective collaboration reduces these risks by fostering a shared understanding of regulatory requirements and inspection expectations.
How Collaboration Improves Compliance Outcomes
Effective collaboration among MAH, QP, and CDMO improves compliance in several measurable ways:
1. Better Audit Readiness
A coordinated audit programme that includes the MAH, QP, and CDMO ensures that site operations and documentation meet regulatory expectations before regulatory inspections occur.
- Joint internal audits, mock inspections, and remediation plans strengthen GMP compliance in pharmaceuticals.
2. Faster Batch Release
When the CDMO and MAH share clear process data and documentation with the QP, batch certification cycles shorten.
- Early and transparent exchange of analytical results, deviations, and change controls enables the QP to perform batch reviews without unnecessary delays.
3. Stronger Deviation and CAPA Handling
Communicating deviations and corrective action, preventive action (CAPA) conclusions across teams ensures that systemic issues are identified and resolved promptly.
- Cross-functional reviews improve data reliability and GMP compliance documentation.
4. Improved Supplier Quality Oversight
Many compliance failures relate to upstream suppliers (raw materials, packaging). A collaborative approach ensures consistent expectations for supplier audits, qualification, and oversight across all stakeholders.
Key Compliance Areas Where Coordination Matters
The most compliance-sensitive areas that benefit from structured collaboration include:
GMP Documentation
Complete, traceable documentation is essential. Shared quality agreements and controlled document management between MAH, CDMO, and the QP ensure accuracy and accessibility.
Quality Agreements
These govern expectations, responsibilities, change control criteria, release testing ownership, complaint handling, and regulatory reporting obligations.
Change Control
Joint involvement in change assessments ensures that regulatory notifications, stability implications, and manufacturing impacts are evaluated consistently.
Deviations / OOS / OOT
Deviations, Out-of-Specification (OOS) and Out-of-Trend (OOT) events should be investigated collectively to avoid disconnects between development, manufacturing, and certification decisions.
Stability Studies and Testing
Accurate stability data underpin product expiry dating and shelf-life assignments. Shared protocols and timely data exchange support regulatory compliance in stability reporting.
Batch Certification Timelines
Planning and data readiness streamline QP batch certification and reduce the risk of regulatory holds.
How Sciom Supports Stronger Collaboration and Quality Oversight
Integrated quality and compliance expertise is a force multiplier for MAH, QP, and CDMO collaboration. Scientific and regulatory partners can help ensure consistency, documentation accuracy, and inspection preparedness.
- Pharmaceutical quality control testing : GMP compliance support and QC testing services by Sciomprovide analytical method development, chemical/physical testing, microbiology testing, and stability studies aligned with ICH/EU GMP expectations.
- Batch release testing services : Batch release testing servicesat Sciom include method transfer, QC physical, Chemical and Microbiology testing and ICH-aligned stability evaluation for robust release decisions.
- Regulatory quality solutions : Sciom provides regulatory services, audit management, and scientific writing that help sponsors prepare and maintain compliance documentation consistent with regulatory submissions.
- QP support services : Sciom's MHRA-approved facility and resident QP capabilities support compliant UK batch release, addressing regulatory expectations for a UK-resident QP within an MHRA Manufacturing and Import Authorisation.
By partnering with quality testing and compliance specialists, sponsors can reinforce internal processes and align CDMO operations with regulatory requirements.
Conclusion
Collaboration between the MAH, QP, and CDMO is not optional, it is a foundational requirement for robust compliance outcomes in pharmaceuticals. Through shared quality systems, aligned documentation, clear quality agreements, and transparent communication, organisations can improve GMP compliance, accelerate batch release, and reduce regulatory risks. For organisations seeking robust compliance and quality oversight, professional partners like Sciom can strengthen internal capabilities and streamline regulatory readiness.